Research
312 results
Name Type Target Compound Name Phase
Tiziana Life Sciences

Direct delivery of anti-IL6 Mabs to the lungs

New Therapies (Antibody-based) IL-6 receptor (CD126) TZLS-501 Pre-Clinical
Roche

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

New Therapies (Antibody-based) IL-6 receptor (CD126) Actemra tocilizumab (RoActemra) Phase III
Collaboration: Regeneron / Sanofi

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

New Therapies (Antibody-based) IL-6 receptor (CD126) Kevzara sarilumab Phase II / III
Chongqing Sidemu Biotechnology Technology

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19

New Therapies (Protein-based) IL15 superagonist; GM-CSF-neutralizing scFv Natural killer (NK) cell therapy Phase I / II
CTK Biotech

RT-PCR and IgM/IgG test kits now available

Research (Testing Kits) IgG/IgM N/A Pre-Clinical
Stanford University

New assay to detect presence of IgM and IgG against SARS-CoV-2 virus with peripheral blood (i.e. fingersticks)

Research (Testing Kits) IgM and IgG antibodies N/A Pre-Clinical
Chongqing Medical University

Antibody responses to SARS-CoV-2 in patients with COVID-19

Research (Antibody Response) IgM and IgG antibodies N/A Phase II
Zydus Cadila

Zydus explores the biologicals route to treat novel Coronaviruswith long-acting Interferon alpha-2b

New Therapies (Small Molecule) Interferon (IFN) alpha receptor PegiHep pegylated interferon alpha-2b Pre-Clinical
Swedish Orphan Biovitrum

A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.

New Therapies (Antibody-based) Interferon gamma Gamifant emapalumab Phase II / III
Swedish Orphan Biovitrum

A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.

New Therapies (Protein-based) Interleukin-1 (IL-1) receptor 1 (IL1R1) Kineret anakinra Phase II / III
Noxopharm

Idronoxil inhibits a key inflammatory pathway involved in a process known as a cytokine storm, which is associated with an abnormally excessive inflammatory response and is believed to be responsible for most deaths in patients with COVID-19 infection

New Therapies (Protein-based) Interleukin-6 (IL-6) Oral idronoxil (NOX-19) Pre-Clinical
Collaboration: Incyte / Novartis

Phase 3 RUXCOVID Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

New Therapies (Small Molecule) Janus kinase-1 (JAK-1); JAK-2 Jakavi ruxolitinib Phase III
Erasme University Hospital

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO)

New Therapies (Peptide) MAS receptor Angiotensin-(1-7) Phase II / III
MediciNova

MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

New Therapies (Small Molecule) MIF; PDE-4; PDE-10 Ibudilast IND
NYU Winthrop Hospital

In seven patients (four female), regardless of anticoagulation status, all autopsies demonstrated platelet-rich thrombi in the pulmonary, hepatic, renal, and cardiac microvasculature. Megakaryocytes were seen in higher than usual numbers in the lungs and heart.

Research (Epidemiology) Megakaryocytes N/A Research
Bonus Biogroup

MesenCure was developed for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients. MesenCure consists of activated Mesenchymal Stromal Cells (“MSCs”) that are isolated from the adipose tissue of healthy donors.

New Therapies (Cell-based) Mesenchymal Stromal cells MesenCure Pre-Clinical
Collaboration: Tonix Pharmaceuticals & Southern Research

Replicating Viral Vector currenly in preclinical testing

Vaccine (Viral Vector) Multiple antigens TNX-1800 Pre-Clinical
University of California, Davis; National Primate Research Center

Non-human primate model of COVID-19 infection to explore therapies, vaccines and effect of age

Research (Non-Human) N/A N/A Pre-Clinical
University of California, San Franscico

UCSF Researchers Aim to Enroll One Million Individuals for Real-Time Epidemiology

Research (Epidemiology) N/A N/A Pre-Clinical
UCSF, Quantitative Bioscience Institute

Reseach of how SARS-CoV-2 hijacks human cells for its own replication

Research (Epidemiology) N/A N/A Pre-Clinical
La Jolla Institute of Immunology

To develop prophylactic/therapeutic antibody preparations

New Therapies (Antibody-based) N/A N/A Pre-Clinical
Colorado State University

Testing and Analysis of SARS-CoV-2 protective gear

Research (Personal Protection) N/A N/A Pre-Clinical
Purdue University

Development of diagnostic tools for SARS-CoV-2

Research (Testing Kits) N/A N/A Pre-Clinical
University of Iowa/ Stanley Pearlman Lab

Exploring inflammation in murine model of SARS-CoV-2 infection and vaccine development

Research (Non-Human) N/A N/A Pre-Clinical
Johns Hopkins University

Genomic sequencing of SARS-CoV-2

Research (Epidemiology) N/A N/A Pre-Clinical